Uveitic Macular News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Uveitic macular. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Uveitic Macular Today - Breaking & Trending Today

Clearside Biomedical (CLSD) Announces Acceptance of Arctic Vision's NDA for Arcatus in Australia

Clearside Biomedical (CLSD) Announces Acceptance of Arctic Vision's NDA for Arcatus in Australia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , South Korea , New Zealand , George Lasezkay , Jenny Kobin Remy Bernarda , Clearside Biomedical Inc , Exchange Commission , Therapeutic Goods Administration , Clearside Biomedical , Arctic Vision , Uveitic Macular , Greater China , Chief Executive Officer , Macular Edema , Drug Administration , Safety Information , Private Securities Litigation Reform Act , Annual Report , Periodic Reports , Media Contacts ,

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

- XIPERE® is referred to as Arcatus by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of. ....

United States , South Korea , New Zealand , Jenny Kobin , George Lasezkay , Remy Bernarda , Therapeutic Goods Administration , Clearside Biomedical Inc , Globenewswire Inc , Drug Administration , Exchange Commission , Arctic Vision , Goods Administration , Uveitic Macular , Chief Executive Officer , Macular Edema , Safety Information , Private Securities Litigation Reform Act , Annual Report , Periodic Reports , Media Contacts ,

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

09.08.2022 - - CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - - Management to Host Webcast and Conference Call . ....

United States , New Zealand , United Kingdom , South Korea , Remy Bernarda , Triamcinolone Acetonide , Susanl Coultas , George Lasezkay , Jenny Kobin , Exchange Commission , American Society Of Retina Specialists , Association For Research , Clearside Biomedical Inc , Host Webcast , Conference Call Today , Chief Executive , Royalty Interest Purchase , Sale Agreement , Healthcare Royalty Partners , Healthcare Royalty , Chief Clinical , Retinal Physician , American Society , Retina Specialists , Ophthalmology Innovation Source , Retina Innovation Summit ,